Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives-Reference-Cited by-同舟云学术

Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives

Published:2020-06-12 Issue:7 Volume:20 Page:531-542
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Sartori Giulia¹,Belluomini Lorenzo¹,Lombardo Fiorella¹,Avancini Alice²,Trestini Ilaria¹,Vita Emanuele³,Tregnago Daniela¹,Menis Jessica⁴⁵,Bria Emilio³,Milella Michele¹,Pilotto Sara¹

Affiliation:

1. Medical Oncology, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata (AOUI) di Verona, Verona, Italy

2. Biomedical, Clinical and Experimental Sciences, Department of Medicine, University of Verona, Verona, Italy

3. Medical Oncology, Università Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario ‘A. Gemelli’ I.R.C.C.S., Roma, Italy

4. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

5. Medical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy

Funder

Italian Association for Cancer Research

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1776119

Reference92 articles.

1. Cancer statistics, 2019

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

4. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer

5. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-10

2. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy;Molecules;2024-03-23

3. Identification of a novel endocytosis‑associated gene signature for prognostic prediction in lung adenocarcinoma;Oncology Letters;2023-10-12

4. Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer;OncoTargets and Therapy;2022-12

5. Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan;Thoracic Cancer;2022-11-24